AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 62 min read$SGHT

Badawi Paul sold $155K of SGHT

Badawi Paul (President and CEO) sold 28,684 shares of Sight Sciences, Inc. (SGHT) at $5.42 ($0.16M total) on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Badawi Paul
Published Jul 6, 2026, 11:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 11:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$SGHT
Neutral
high confidence
Mentioned
$SGHT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGHTNeutralLow
01

Why it matters

The disclosed sale is a sentiment datapoint; absent additional corporate developments, it is unlikely to drive a durable repricing.

02

Market read

Insider selling at $5.42/share is newly disclosed, but the 10b5-1 designation reduces interpretive weight.

03

What to watch

The filing does not disclose intent beyond the plan; traders should avoid inferring signal without corroborating news (guidance, trial, financing, or regulatory updates).

Relevance 3/10Novelty 4/10Timing: New Form 4 filed 2026-07-06 after-hours

Background

The article is a SEC Form 4 insider transaction disclosure for Sight Sciences, Inc.

Company-level read

Ticker impact

$SGHTNeutralHigh confidence
Context

Sight Sciences CEO Badawi Paul sold 28,684 shares on 2026-07-01 at $5.42/share under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction should be muted given the stated 10b5-1 pre-arranged plan.

Evidence & confidence

Form 4 provides transaction mechanics (size, price, date) but no new company-specific operational or financial information.

Market effects

Sector

No clear sector read-through; this is an issuer-specific insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Sight Sciences, Inc.

    Subject of the Form 4 insider transaction; CEO/President Badawi Paul sold shares.

  • insider
    Badawi Paul

    President and CEO; reported open-market sale under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SGHT insider trading history →

Related articles

AUG 20
$SGHTHighAI 8/10

FDA Broadens ‘Indications for Use’ for Sight Sciences’ TearCare System

Sight Sciences (SGHT) announced FDA expanded the TearCare System's use to improve meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first treatment indicated for this purpose, according to the company. The update also includes optional debridement, enhancing its approach to treating the condition. SGHT reported Q2 2026 revenue growth and updated its full-year guidance earlier this month.

visionmonday.com2 min
AUG 19
$SGHTMedAI 8/10

Sight Sciences, Inc.: TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA approval for its TearCare System to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). This makes TearCare the first and only treatment indicated for this purpose, expanding its market potential. The company's CEO and a medical expert highlighted the significance of this milestone in dry eye disease treatment.

finanznachrichten.de2 min
AUG 19
$SGHTHighAI 8/10

TearCare is the first and only treatment indicated to improve gland function in dry-eye patients

Sight Sciences (SGHT) announced that the FDA expanded the TearCare System's indication to include improving meibomian gland function in adults with evaporative dry eye disease due to MGD. This makes TearCare the first and only treatment with this indication, effective August 18, 2026. The update also incorporates optional debridement into the system's treatment approach.

stocktitan.net2 min
AUG 19
$SGHTMedAI 8/10

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences (SGHT) announced FDA expanded approval for its TearCare System, now the only treatment indicated to improve meibomian gland function in patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD). The update includes optional debridement, enhancing its comprehensive approach to treating MGD. According to the company, this milestone reflects its commitment to advancing dry eye disease treatment.

globenewswire.com2 min
AUG 13
$SGHTMedAI 8/10

Sight Sciences (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences (SGHT) reported Q2 2026 revenue of $23.4M, up 20% y/y, driven by Interventional Glaucoma ($20.7M) and Interventional Dry Eye ($2.7M). Gross margin rose to 91% from 85%. Net loss was $4.4M. FY2026 revenue guidance raised to $88M-$92M; adjusted opex guidance lowered to $92M-$94M. Alcon patent appeal remains pending.

fool.com7 min